Retevmo Manufactured by Lilly is FDA-approved to treat a specific type of non-small cell lung cancer (NSCLC)in adults.
Retevmo is used for NSCLC that is metastatic. This means the cancer has spread to many other areas of the body outside of the lungs.
For this purpose, the NSCLC must also have abnormal changes in the RET gene. Specifically, the NSCLC must be RET fusion-positive, meaning the RET gene must contain a certain fusion protein. (Fusion proteins result from proteins on the RET gene combining with genes from a different protein.)
Before starting Retevmo, your doctor will do a biopsy (remove a small sample of the tumor to test) to check the genetic makeup of your NSCLC. If your NSCLC is found to be RET fusion-positive, your doctor may recommend treatment with Retevmo.
Retevmo works by targeting cancer cells that have changes in the RET gene. The drug works by keeping these cancer cells from growing and spreading throughout your body.